<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565601</url>
  </required_header>
  <id_info>
    <org_study_id>PSS2018/AR052-DECKER/MS</org_study_id>
    <nct_id>NCT03565601</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Anti-Ro52 Antibodies in Connective Tissue Diseases (a-Ro52)</brief_title>
  <acronym>a-Ro52</acronym>
  <official_title>Phenotypic Features and Prognostic Value of Anti-Ro52 (TRIM-21) Antibodies in Connective Tissue Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases.
      Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a
      factor associated with disease severity (interstitial lung disease, vasculopathy) and
      cancers. The aim of this study is to assess interstitial lung disease and vasculopathy
      prevalence and severity, cancers occurence and others clinical features of connective tissue
      disease patients with anti-Ro52 autoantibodies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ILD prevalence</measure>
    <time_frame>baseline (J0)</time_frame>
    <description>Clinical (cough, dyspnea) and/or radiological (tomodensitometry) data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ILD severity</measure>
    <time_frame>baseline (J0)</time_frame>
    <description>PFT (pulmonary function test): FVC, FEV1, DLCO (percentages of predicted values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasculopathy occurence</measure>
    <time_frame>baseline (J0) and follow-up</time_frame>
    <description>Raynaud disease, digital ulcers or gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer occurence</measure>
    <time_frame>baseline (J0) and follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>CTD patients with anti-Ro52 antibodies</arm_group_label>
    <description>Connective tissue disease patients with anti-Ro52 antibodies at diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTD patients without anti-Ro52 antibodies</arm_group_label>
    <description>Connective tissue disease patients without anti-Ro52 antibodies at diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up</intervention_name>
    <description>Clinical data, radiological data and laboratory tests follow-up</description>
    <arm_group_label>CTD patients with anti-Ro52 antibodies</arm_group_label>
    <arm_group_label>CTD patients without anti-Ro52 antibodies</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with connective tissue disease (differenciated or not) and anti-Ro52 antibodies
        (as single specificity or associated with other autoantibody specificities) at diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Connective tissue disease (differenciated or not)

          -  Presence of anti-Ro52 antibodies at diagnosis

        Exclusion Criteria:

          -  Healthy subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland JAUSSAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul DECKER, MR</last_name>
    <role>Study Director</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland JAUSSAUD, Pr</last_name>
    <phone>0383154067</phone>
    <email>R.JAUSSAUD@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul DECKER, MR</last_name>
    <email>decker.paul57130@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Private Hospital</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MAURIER, Dr</last_name>
      <email>francois.maurier@hp-metz.fr</email>
    </contact>
    <investigator>
      <last_name>François MAURIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011 Jul;10(9):509-13. doi: 10.1016/j.autrev.2011.03.004. Epub 2011 Apr 5.</citation>
    <PMID>21447407</PMID>
  </reference>
  <reference>
    <citation>Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int. 2017 Aug;37(8):1323-1333. doi: 10.1007/s00296-017-3718-1. Epub 2017 Apr 17. Review.</citation>
    <PMID>28417151</PMID>
  </reference>
  <reference>
    <citation>Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M; Canadian Scleroderma Research Group (CSRG), Fritzler MJ. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012 Mar 6;14(2):R50. doi: 10.1186/ar3763.</citation>
    <PMID>22394602</PMID>
  </reference>
  <reference>
    <citation>Gunnarsson R, El-Hage F, Aaløkken TM, Reiseter S, Lund MB, Garen T; Norwegian MCTD study group, Molberg Ø. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2016 Jan;55(1):103-8. doi: 10.1093/rheumatology/kev300. Epub 2015 Aug 28.</citation>
    <PMID>26320136</PMID>
  </reference>
  <reference>
    <citation>Murng SHK, Thomas M. Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases. J Clin Pathol. 2018 Jan;71(1):12-19. doi: 10.1136/jclinpath-2015-203587. Epub 2017 Jun 29.</citation>
    <PMID>28663326</PMID>
  </reference>
  <reference>
    <citation>Reiseter S, Gunnarsson R, Mogens Aaløkken T, Lund MB, Mynarek G, Corander J, Haydon J, Molberg Ø. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford). 2018 Feb 1;57(2):255-262. doi: 10.1093/rheumatology/kex077.</citation>
    <PMID>28379478</PMID>
  </reference>
  <reference>
    <citation>Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, Fiehn C. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.150844. Epub 2016 Jun 1.</citation>
    <PMID>27252419</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

